In addition, quizartinib is an another selective FLT3 (target of gilteritinib) inhibitor that is also effective to combine with abemaciclib to inhibit proliferation of lung cancer cells, suggesting that FLT3 might confer synthetic lethality to CDK4/6 inhibition. Here, CDK4 is linked to lung carcinoma.